Tracers / [131I]MIBG
[131I]MIBG
Also written as MIBG; [I-131]MIBG; I-131-MIBG; mIBG; [I-131]mIBG; [I-131]meta-iodobenzylguanidine
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- approved
- Syntheses indexed
- 19
What it is
- Compound class
- Radioiodinated benzylguanidine (norepinephrine analog)
- Target / mechanism
- Norepinephrine transporter PMID 39978816
- Clinical application
- Targeted radionuclide therapy of neuroendocrine tumors (neuroblastoma, pheochromocytoma/paraganglioma) PMID 9649115
- Theranostic pair
- <a href="/tracers/i123-mibg/">i123-mibg</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 19889235 2009 World J Surg Oncol |
| — | — | — | — | — | — | 42454478 2026 Endocr Relat Cancer |
| — | — | — | — | — | — | 41528635 2026 Ann Nucl Med |
| — | — | — | — | — | — | 41083371 2026 Endocr J |
| — | — | — | — | — | — | 40583575 2025 J Radiat Res |
| — | — | — | — | — | — | 40131534 2025 Cancer Immunol Immunother |
| — | — | — | — | — | — | 39978816 2025 J Nucl Med |
| — | — | — | — | — | — | 39909450 2025 Fukushima J Med Sci |
| — | — | — | — | — | — | 39351526 2024 Front Endocrinol (Lausanne) |
| — | — | — | — | — | — | 37725921 2024 Neuroendocrinology |
| — | custom manifold | — | — | — | Resin-supported MBG precursor Progenics Pharmaceuticals, Inc., a Lantheus company | 35861867 2022 Clin Cancer Res |
| — | — | — | — | — | — | 34475242 2021 J Nucl Med |
| — | — | — | — | — | — | 34417933 2021 EJNMMI Radiopharm Chem |
| — | — | — | — | — | — | 30854332 2019 Front Oncol |
| — | — | — | — | — | — | 30100938 2018 Nucl Med Mol Imaging |
| Manual synthesis | — | — | — | — | — | 9649115 1998 Br J Cancer Using a no-carrier-added synthesis route, we produced 123I-, 125I-, 131I- and 211At-labelled benzylguanidines |
| — | — | — | — | — | — | 41746475 2026 Paediatr Drugs |
| — | — | — | — | — | — | 36301465 2023 Ann Nucl Med |
| — | — | — | — | — | — | 11762352 2001 Ann Oncol |
Need this precursor?We can point you to suppliers for [131I]MIBG, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 78 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - I-123. Stage set/updated at stage 23 from PMID 34475242: 'the recent approval of high-specific-activity 131I-MIBG for metastatic or inoperable pheochromocytoma or paraganglioma by the U.S. Food and Drug Administration has resulted in general availability of, and renewed interest in, this treatment.'. | Stage 28: added indication(s) onc-neuroblastoma from consolidated missing-rubric review.